Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Yali Xu Author

xu@gmail.com

Subjects of specialization
Anthracycline, Cardiotoxicity, Lymphoma, Speckle-tracking echocardiography

Affiliation
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Biography

Yali Xu was working in the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. He has more than 50 publications. His research area related to Anthracycline. He has more than 40 publications. His current research area related to osteoarthropathy. He is specialised in Anthracycline; Cardiotoxicity; LVEF; Lymphoma; Speckle-tracking echocardiography, 2D; Strain

Publications

Research Article Open Access

Early Changes in 2D-Speckle-Tracking Echocardiography May Predict a Decrease in Left Ventricular Ejection Fraction in Lymphoma Patients Undergoing Anthracycline Chemotherapy: A Pilot Study

Author(s):

Yali Xu, Joerg Herrmann, Patricia A Pellikka, Stephen M. Ansell,Stephen S Cha and Hector R Villarraga

Background: Two-dimensional speckle-tracking echocardiography (2D-STE) may detect early changes in cardiac mechanics in patients with normal left ventricular ejection fraction (LVEF). We aimed to evaluate whether changes in strain or strain rate, as measured by 2D-STE, precede a decrease in LVEF in patients with lymphoma undergoing anthracycline-based chemotherapy (AC).

Methods: We studied patients with lymphoma who und... view more»

DOI: 10.4172/2324-9110.1000134

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP